 |
인쇄하기
취소
|
KFDA approves Galvus, new oral treatment for type 2 diabetes
Novartis Korea says the Korea Food and Drug Administration (KFDA) has approved Galvus (vildagliptin), a new oral treatment for type 2 diabetes.
As a member of the new class of dipeptidyl peptidase IV inhibitors (DPP-IV), Galvus works through a novel mechanism of action by targeting the dysfunction in the pancreatic islets that causes high blood sugar levels in people with type 2 diabetes. Is...
As a member of the new class of dipeptidyl peptidase IV inhibitors (DPP-IV), Galvus works through a novel mechanism of action by targeting the dysfunction in the pancreatic islets that causes high blood sugar levels in people with type 2 diabetes. Is...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.